{"id":"NCT01646671","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients","officialTitle":"A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2012-07-20","resultsPosted":"2015-09-07","lastUpdate":"2015-10-23"},"enrollment":35,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hypertension"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]},{"type":"DRUG","name":"LCZ696","otherNames":[]},{"type":"DRUG","name":"LCZ696","otherNames":[]}],"arms":[{"label":"LCZ696 200 mg","type":"EXPERIMENTAL"},{"label":"LCZ696 400 mg","type":"EXPERIMENTAL"},{"label":"LCZ696 400 mg plus other hypertension (HTN) medications","type":"EXPERIMENTAL"}],"summary":"This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths","timeFrame":"Week 8","effectByArm":[{"arm":"LCZ696 200 mg","deltaMin":20,"sd":null},{"arm":"LCZ696 400 mg","deltaMin":12.5,"sd":null},{"arm":"LCZ696 400 mg Plus Other Hypertension (HTN) Medications","deltaMin":33.3,"sd":null},{"arm":"Total Participants","deltaMin":48.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":9,"countries":["Japan"]},"refs":{"pmids":["26402918"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":35},"commonTop":["NASOPHARYNGITIS","BLOOD CREATINE PHOSPHOKINASE INCREASED","HYPERURICAEMIA"]}}